Members Archive - MassBio https://www.massbio.org/members/ Massachusetts Biotechnology Council Fri, 05 Jan 2024 07:02:07 +0000 en-US hourly 1 https://wordpress.org/?v=6.3.2 Ropes & Gray https://www.massbio.org/members/ropes-gray/ Fri, 05 Jan 2024 02:02:07 +0000 https://www.massbio.org/members/ropes-gray/ When clients come to Ropes & Gray, they find a global team of more than 1,100 professionals, whose top-notch skills, varied backgrounds and unique perspectives can help them meet high-stakes challenges, solve complex problems and reach their goals. An international presence, the firm has offices in New York, Washington, D.C., Boston, Chicago, San Francisco, Silicon […]

The post Ropes & Gray appeared first on MassBio.

]]> When clients come to Ropes & Gray, they find a global team of more than 1,100 professionals, whose top-notch skills, varied backgrounds and unique perspectives can help them meet high-stakes challenges, solve complex problems and reach their goals. An international presence, the firm has offices in New York, Washington, D.C., Boston, Chicago, San Francisco, Silicon Valley, London, Hong Kong, Shanghai, Tokyo and Seoul.

The attorneys and technical specialists who make up the global life sciences group understand the unique needs of a wide range of clients in the dynamic life sciences industry. We work across practices and geographies to develop cutting-edge solutions that help our clients meet their business goals.

In addition to advising biotechnology, pharmaceutical and medical device companies, we also work with:

• Investment banks, venture capital and private equity firms, royalty monetization firms, private investment and hedge funds, and individual investors focused on funding life sciences-related companies
• Food, dietary supplement, cosmetics and consumer product companies
• Academic medical centers and research institutions
• Veterinary, agricultural and industrial applications

Drawing on resources in our offices around the globe, we focus on developing cutting-edge solutions to help clients meet their business goals. Our practice includes:

• Mergers & acquisitions
• Licensing, collaborations & joint ventures
• Public and private financings and SEC compliance
• FDA regulatory and health care compliance
• China regulatory & compliance
• Government enforcement / white collar crime
• Intellectual property
• Securities & futures enforcement
• Antitrust
• Tax

The post Ropes & Gray appeared first on MassBio.

]]> SBH Sciences, Inc. https://www.massbio.org/members/sbh-sciences-inc/ Fri, 05 Jan 2024 02:02:07 +0000 https://www.massbio.org/members/sbh-sciences-inc/ SBH Sciences is a preclinical CRO based in Boston metro west providing biology products and services in support of small molecule and large molecule therapeutic and diagnostic programs in oncology, inflammation and other human diseases. SBH Sciences specializes in in vitro pharmacology through cell-based assays and biologics production, and has been a part of the […]

The post SBH Sciences, Inc. appeared first on MassBio.

]]> SBH Sciences is a preclinical CRO based in Boston metro west providing biology products and services in support of small molecule and large molecule therapeutic and diagnostic programs in oncology, inflammation and other human diseases. SBH Sciences specializes in in vitro pharmacology through cell-based assays and biologics production, and has been a part of the Massachusetts biotech community since 1997, serving over 150 customers, globally. SBH is a major supplier of cytokines and antibody-related cytokines, among other clinically-important biologics, and related services include cytokine potency assays and other biosimilar characterization tests. SBH Sciences partners actively with other service specialists and through these partner networks, SBH Sciences customers can access a full range of discovery and preclinical capabilities. SBH Sciences recently announced the formation of a strategic partnership with Woodland Pharmaceuticals to create a new business entity: Woodland Biosciences, which extends SBH’s discovery capabilities to in vivo disease modeling. Woodland Biosciences now offers in vivo animal efficacy modeling in Massachusetts, including human cancer cell-line and patient-derived tumor xenograft models, including PK/PD analyses with safety-related animal studies available through the partner’s Quebec connections. SBH Sciences and Woodland Pharmaceuticals have also partnered to form Woodland Translational Research Canada, which is a co-recipient of $15 million funding from the Canadian Government to develop methods and processes for better patient cancer treatment. The approach combines genetic analyses with preclinical trial design in what is referred to as “Mouse Avatar” technology where patient tumors are grown and analyzed for drug sensitivity in mice, in parallel with the patient. This methodology enables a real-time screening test for direct drug comparison testing that is impossible when the test subject is a single, live person in the clinical setting. SBH Sciences has made substantial investments in biomarker analysis capabilities, through its partner SBH Diagnostics. Key among the expanding capabilities is a new Peggy Sue by Simple Western that enables rapid and high throughput 2-D western analysis of ultra-small protein samples by either charge or size in an automated 96 well capillary format. Coupled with SBH’s automated ELISA, Luminex and traditional westerns this suite of capabilities rounds out their biomarker service portfolio. Our array of cytokine bioassay services is the most comprehensive in the US and includes over 300 bioassays that can accelerate discovery and biopharma development programs. Moreover, our proprietary processes have achieved commercial production of 31 highly purified recombinant cytokines, 8 enzymes and 35 monoclonal antibodies, currently sold to the scientific community worldwide. SBH Sciences is based in Natick, MA. Our Innovative Process Development Solutions offer unique opportunity to utilize our capabilities including: – One-stop sourcing of your complete pharmacology needs from hit –to-lead and lead optimization through efficacy and mechanism IND-enabling studies as well as companion biomarkers and diagnostics. – Cellular Biology (e.g., transient and stable mammalian cell transfection, select clones and demonstrate expression). – Cell Culture (e.g., serum-free media optimization, adaptation to suspension, production of cell lysates). – Protein Recovery and Purification (e.g., optimizing cross flow filtration, streamline chromatography, eliminate solvent utilization). – Analytical assay (e.g., HPLC, ELISA, Luminex, Multiplex, Western). – Cell-Based assay (e.g., proliferation and neutralization bioassay, agonist and antagonist screening, ADCC). – Mid-scale production and purification of drug substance for preclinical study. Working with SBH Sciences offers several key elements to improve your outcomes: – Streamlining of your process – Significant reduction of development time – Increasing yield while maintaining exceptional purity of the final product We assure strict confidentiality and superior execution which will be delivered on a timely basis and cost effective manner. SBH Sciences is determined to maintain the highest standards and deliver the highest quality products and services. SBH Sciences welcomes suggestions from researchers and encourage you to communicate with us about your particular research needs.

The post SBH Sciences, Inc. appeared first on MassBio.

]]> Indigo https://www.massbio.org/members/indigo/ Fri, 05 Jan 2024 02:02:06 +0000 https://www.massbio.org/members/indigo/ Alongside growers and buyers, we are building a system responsive to demands for high quality and sustainably produced food and fiber. Indigo develops microbial and digital technologies that improve grower profitability, environmental sustainability, and consumer health. These technologies underpin its pioneering business model, which spans agriculture’s full value chain.

The post Indigo appeared first on MassBio.

]]> Alongside growers and buyers, we are building a system responsive to demands for high quality and sustainably produced food and fiber. Indigo develops microbial and digital technologies that improve grower profitability, environmental sustainability, and consumer health. These technologies underpin its pioneering business model, which spans agriculture’s full value chain.

The post Indigo appeared first on MassBio.

]]> Rilas Technologies, Inc. https://www.massbio.org/members/rilas-technologies-inc/ Fri, 05 Jan 2024 02:02:06 +0000 https://www.massbio.org/members/rilas-technologies-inc/ Rilas Technologies, Inc. provides innovative and cost-effective solutions for medicinal chemists facing analytical and purification challenges for biomolecules and small molecules. Our business model of customer success is our success allows us to take custom approaches with each customer to ensure successful purification and analytical results. At our Woburn, MA laboratory, our state of the […]

The post Rilas Technologies, Inc. appeared first on MassBio.

]]> Rilas Technologies, Inc. provides innovative and cost-effective solutions for medicinal chemists facing analytical and purification challenges for biomolecules and small molecules. Our business model of customer success is our success allows us to take custom approaches with each customer to ensure successful purification and analytical results. At our Woburn, MA laboratory, our state of the art equipment allows us to provide the highest quality purification and analysis of compounds for our customers. Rilas Technologies also has insourcing and consulting options for our customers that have internal purification needs.

The post Rilas Technologies, Inc. appeared first on MassBio.

]]> Dyno Therapeutics https://www.massbio.org/members/dyno-therapeutics/ Thu, 04 Jan 2024 16:03:05 +0000 https://www.massbio.org/members/dyno-therapeutics/ The post Dyno Therapeutics appeared first on MassBio.

]]> The post Dyno Therapeutics appeared first on MassBio.

]]> Stoke Therapeutics https://www.massbio.org/members/stoke-therapeutics/ Thu, 04 Jan 2024 15:32:07 +0000 https://www.massbio.org/members/stoke-therapeutics/ Stoke Therapeutics, Inc. (Nasdaq: STOK), is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases […]

The post Stoke Therapeutics appeared first on MassBio.

]]> Stoke Therapeutics, Inc. (Nasdaq: STOK), is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the company on Twitter at @StokeTx.

The post Stoke Therapeutics appeared first on MassBio.

]]> Flagship Pioneering https://www.massbio.org/members/flagship-pioneering/ Thu, 04 Jan 2024 15:32:07 +0000 https://www.massbio.org/members/flagship-pioneering/ Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates through two synergistic units: VentureLabsTM which invents and launches transformative companies, and Venture Capital, which finances and realizes innovative, early-stage companies. Founded in 2000, and based in Cambridge, Massachusetts, Flagship Ventures manages over $900 million in capital. The Flagship team innovates and invests […]

The post Flagship Pioneering appeared first on MassBio.

]]> Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates through two synergistic units: VentureLabsTM which invents and launches transformative companies, and Venture Capital, which finances and realizes innovative, early-stage companies. Founded in 2000, and based in Cambridge, Massachusetts, Flagship Ventures manages over $900 million in capital. The Flagship team innovates and invests in three principal business sectors: therapeutics, health technologies and sustainability/clean technology. Past successful Flagship portfolio ventures include: Adnexus (acquired by Bristol-Myers Squibb), Accuri Cytometers (acquired by Becton, Dickinson), Morphotek (acquired by Eisai), Color Kinetics (acquired by Philips), AVEO (NASDAQ: AVEO) and BG Medicine (NASDAQ: BGMD). Recent notable portfolio ventures include: Joule Unlimited, Agios, Affinnova, AeroDesigns and Novomer. For more information, please visit www.flagshipventures.com.

The post Flagship Pioneering appeared first on MassBio.

]]> TandemAI https://www.massbio.org/members/tandemai/ Thu, 04 Jan 2024 14:32:10 +0000 https://www.massbio.org/members/tandemai/ The post TandemAI appeared first on MassBio.

]]> The post TandemAI appeared first on MassBio.

]]> Fulcrum Therapeutics https://www.massbio.org/members/fulcrum-therapeutics/ Thu, 04 Jan 2024 14:32:09 +0000 https://www.massbio.org/members/fulcrum-therapeutics/ Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum was launched in 2016 by Third Rock Ventures, and is […]

The post Fulcrum Therapeutics appeared first on MassBio.

]]> Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass.

The post Fulcrum Therapeutics appeared first on MassBio.

]]> InnoVenture Labs https://www.massbio.org/members/north-shore-innoventures/ Thu, 04 Jan 2024 14:02:07 +0000 https://www.massbio.org/members/north-shore-innoventures/ North Shore InnoVentures operates the Biotech InnoVenture Center (BIVC), providing business acceleration/incubation services for early-stage biotech companies within the North Shore’s growing life sciences cluster and creating opportunities for scientific and business collaboration. Through shared physical resources and mentoring by experienced entrepreneurs and investor advisers we guide early-stage companies to focus their business plans, conserve […]

The post InnoVenture Labs appeared first on MassBio.

]]> North Shore InnoVentures operates the Biotech InnoVenture Center (BIVC), providing business acceleration/incubation services for early-stage biotech companies within the North Shore’s growing life sciences cluster and creating opportunities for scientific and business collaboration. Through shared physical resources and mentoring by experienced entrepreneurs and investor advisers we guide early-stage companies to focus their business plans, conserve capital, build strong teams and achieve development and funding milestones rapidly and efficiently.

The post InnoVenture Labs appeared first on MassBio.

]]>